OPTIMIZATION OF THE HEART RATE CONTROL IN ATRIAL FIBRILLATION BY MONITORING OF THE DIGOXIN CONCENTRATION IN ELDERLY PATIENTS

Author:

Zadvorev S. F.,Yakovlev A. A.,Pushkin A. S.,Rukavishnikova S. A.,Filippov A. E.,Obrezan A. G.

Abstract

Background. Digoxin takes important place in the management of patients with paroxysmal or persistent atrial fibrillation (AF). Monitoring of serum digoxin concentration (SDC) seems to be perspective way to improve the safety and efficacy of treatment. At the same time, there are no generally accepted reference ranges for SDC, especially in terms of the onset of therapy.Aim. To evaluate the potential contribution of SDC monitoring in the context of efficacy of AF treatment with the use of digoxin in elderly patients.Material and methods. A retrospective analysis of treatment of patients with recent-onset (n=91) or permanent (n=58) AF was performed. In all cases, the strategy of heart rate (HR) control was realized, including treatment with digoxin in 104 cases. SDC was measured twice during the digitalization: 20 hours after the first digoxin dose, and at the endpoint (time of sinus rhythm spontaneous restoration or, if the rhythm not restored, on day 7 of AF persistence).Results. The influence of digoxin on HR was dose-dependent since the 1st week of therapy, and the SDC dynamics was strictly associated with change in HR (r=-0.66, p<0.001). There was a negative correlation between the probability of the sinus rhythm restoration due to digoxin therapy and the SDC: its probability in high SDC was significantly lower compared to other approaches to the HR control (0% vs 76% in beta-blocker monotherapy; and vs 100% in therapy with beta-blocker + lower-SDC, p=0.036). In patients with persisted AF and low SDC, the digoxin was withdrawn more often due to lack of clinical efficiency.Conclusions. The SDC monitoring at the 1st week of digitalization could be used to improve the efficacy of therapy and to minimize the risks of spontaneous rhythm restoration, if not desired, and to reveal the disproportion between its high dose and low efficacy. The role of this diagnostic tool seems to be limited to safety control and negative predictive value for efficacy (the lower concentration, the higher risk of inefficiency), whereas its positive predictive value in terms of efficacy seems contradictory. The obtained data could be used for decision-making for recommendation of longterm digoxin usage if its contribution into HR control is doubtful. 

Publisher

Stolichnaya Izdatelskaya Kompaniyaizdat

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Reference15 articles.

1. Strelnikov A.A., Obrezan A.G., Shaydakov E.V. Screening and prophylaxis for internal diseases. Saint Petersburg: SpetsLit: 2012. (In Russ.) [Стрельников А.А., Обрезан А.Г., Шайдаков Е.В. Скрининг и профилактика актуальных заболеваний. СПб.: СпецЛит: 2012].

2. Ziff O.J., Kotecha D. Digoxin: the good and the bad. Trends in Cardiovascular Medicine. 2016;26(7):585-95. doi: 10.1016/j.tcm.2016.03.011.

3. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi: 10.1093/eurheartj/ehw210.

4. Revishvili A.S., Shlyakhto Y.V., Sulimov V.A. et al. Diagnosis and treatment of atrial fibrillation. Clinical guidelines (2017). [cited 2018 Jan 25]. Available from: https://racvs.ru/clinic/files/2017/AtrialFibrillation.pdf (In Russ.) [Ревишвили А.Ш., Шляхто Е.В., Сулимов В.А. и др. Диагностика и лечение фибрилляции предсердий. Клинические рекомендации (2017). [цитировано 25.01.2018]. Доступно на: https://racvs.ru/clinic/files/2017/Atrial-Fibrillation.pdf].

5. The Digitalis in acute atrial fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicenter trial in 239 patients. Eur Heart J. 1997;18:649-54.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3